Additionally, gonadotropin‐releasing hormone analog (GnRHa) therapy decreases TGF‐βRs, SMAD3 and SMAD4 along with an increase in SMAD7 expression in both myometrium and leiomyoma tissues compared to untreated control.42 Here, SMAD4 is linked to leiomyoma.